MedTrace Logo

Avatrombopag for the Treatment of Thrombocytopenia in Adults With Chronic Liver Disease Undergoing a Procedure

NCT03554759 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2024-10-21

No results posted yet for this study

Summary

Phase 4 observational cohort study to characterize the treatment patterns and effects of avatrombopag use in patients with thrombocytopenia associated with chronic liver disease who are either undergoing, or have already undergone, a procedure.

Conditions

Interventions

DRUG

Avatrombopag

Avatrombopag dosing will be determined by the treating physician in conjunction with the FDA-approved package insert.

Sponsors & Collaborators

  • Sobi, Inc.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-02
Primary Completion
2019-01-31
Completion
2019-01-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03554759 on ClinicalTrials.gov